Brazil's R&D-based industry outlines priorities for new president
This article was originally published in SRA
Executive Summary
With Brazil's new president, Dilma Rousseff, to be inaugurated in January, the pharmaceutical industry has a list of issues that it would like the government to tackle. Greater pricing freedom and reducing the time it takes to grant a patent are just two priorities, explains Jorge Raimundo, president of the advisory council of Interfarma, Brazil's R&D-based industry association1.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.